PCM
BHVN

Prelude Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Prelude Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100
Closed -$4K – 2469
2019
Q3 		$4K Sell
100
-2,800
-97% -$118K ﹤0.01% 1593
2019
Q2 		$127K Buy
+2,900
New +$163K 0.01% 872
2018
Q2 		– Sell
-39,700
Closed -$1.02M – 2170
2018
Q1 		$1.02M Buy
+39,700
New +$1.19M 0.07% 277

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Prelude Capital Management's BHVN Position: Q4 2022 in Review

Prelude Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 35,549 shares — an estimated $5.37M sold.

Prelude Capital Management first reported a position in BHVN in Q3 2018 and held it in 8 quarters. The position peaked at $7.48M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Prelude Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 35,549 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $5.37M.
  • Prelude Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 8 quarters.
  • Prelude Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7.48M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.